SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA granted full approval to Ultragenyxs Fayuvi/UX111 gene therapy for pediatric Sanfilippo syndrome type A, along with a Priority Review Voucher, making it the first approved treatment for the disorder. Traders are debating the muted share-price reaction, with bullish views emphasizing the new commercial product and voucher value while skeptics cite limited market size, cash burn, and commercialization risk.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that states can regulate sports-event contracts as gambling, rather than federally regulated swaps, is drawing attention as a potential setback for Kalshi and other prediction-market rivals. Traders debate whether the decision strengthens DraftKings competitive position, while others note that appeals, regulatory uncertainty, prediction-market execution, and sportsbook margins remain risks.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Ryan Cohens reported open-market purchase of GameStop shares is fueling renewed bullish interest, alongside speculation about additional buybacks and a possible Roaring Kitty return. Traders are debating whether the steady climb, elevated borrowing costs and options activity could pressure shorts, while others caution that low volume and range-bound trading weaken the squeeze case.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is drawing attention after a steep post-earnings selloff, with traders citing its premium valuation, slower expected comparable-sales growth, rising costs and weakening discretionary demand. Bulls view the decline as oversold and point to continued store expansion and strong operating performance, while bears remain focused on valuation, competition and concerns around the Salad and Go expansion plans and potential dilution.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

A sharp rally to new highs has driven attention to Zcash, with traders attributing momentum to its privacy-focused Bitcoin alternative narrative, strong relative performance, and short liquidations. Bullish traders expect continued adoption and further upside, while skeptics describe the move as FOMO-driven and overextended, warning of a potential pullback.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is drawing attention after announcing a convertible-debt financing and an at-the-market share-sale program, intensifying concerns about leverage, dilution and managements timing. Traders remain divided, with bears focused on financing costs and shareholder dilution while bulls argue that higher-priced compute contracts, strong customer commitments and expanded contracted power justify the capital investment.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Federal Reserves rate hike and hawkish outlook for additional tightening have put IWM in focus, as traders view small caps as especially sensitive to higher borrowing costs and Treasury yields. The community is predominantly bearish on the Russell 2000s technical weakness, though some traders argue the move was largely priced in and expect a short-term relief bounce.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

An upbeat quarterly update and highly praised management presentation have fueled a sharp rally, reinforcing optimism around Schrodingers AI-powered drug-discovery platform, software growth, and pharmaceutical partnerships. Traders remain divided over whether the move can continue, with some citing overbought conditions and attempting to short the surge while others view it as the start of a broader re-rating.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generacs multiyear agreement to supply backup generators for Amazon data centers has driven a sharp rally and renewed attention to the company as an AI infrastructure and power-demand beneficiary. Traders are broadly bullish on the added data-center revenue visibility, while others are debating profit-taking, valuation, warrant-related dilution, and whether the initial surge can hold.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A sharp semiconductor and AI-led rebound has lifted AMD, with traders emphasizing bullish momentum, heavy call activity and potential short-covering. Others argue the move is overextended and valuation risks, further rate hikes and broader AI-sector concerns could trigger a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Here’s Why

Equity

Barclays raised Iovance’s price target to $15 from $13 while maintaining an ‘Overweight’ rating, according to The Fly.


This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally

The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.

RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares

RARE investors are now awaiting an FDA decision on UX111, the company’s one-time gene therapy for Sanfilippo syndrome type A.


Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.


Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next

Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.

IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’

Iovance executive Brian Gastman said on Tuesday at a conference that the company’s science was never the hindrance, but getting its therapy to patients. 

VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4

Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.

SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals 

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

CLOV Stock Hits Over 2-Month High As Humana Deal Buzz Builds Ahead Of Investor Conferences 

Humana listed Counterpart Health among the vendors for its provider-performance and quality programs.

NVO Stock Logs Worst Week Since February As Novo Nordisk Rebrands To ‘Novo’ Amid Another Gloomy Year 

NVO has fallen about 12% in 2026 after losing more than half its value in 2025, its worst year since 1984.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

Bullish Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Feed

News

Sentiment

Fundamentals

Info

XBI SPDR S&P Biotech ETF

Fundamentals

Latest XBI News